Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-855-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
OptionableNot Optionable
Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions
What is Tenax Therapeutics' stock symbol?
Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."
When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?
Shares of Tenax Therapeutics reverse split before market open on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.
How were Tenax Therapeutics' earnings last quarter?
Tenax Therapeutics Inc (NASDAQ:TENX) issued its quarterly earnings data on Tuesday, August, 14th. The specialty pharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.00) by $0.29. View Tenax Therapeutics' Earnings History.
Has Tenax Therapeutics been receiving favorable news coverage?
Media coverage about TENX stock has been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tenax Therapeutics earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Tenax Therapeutics' key competitors?
Who are Tenax Therapeutics' key executives?
Tenax Therapeutics' management team includes the folowing people:
- Mr. Anthony A. DiTonno, CEO & Director (Age 71)
- Mr. Michael B. Jebsen, Pres & CFO (Age 48)
- Mr. John P. Kelley, Consultant (Age 65)
- Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
- Maria Isabel Tomargo, Assistant VP of Marketing & Sales
Who are Tenax Therapeutics' major shareholders?
Which major investors are buying Tenax Therapeutics stock?
How do I buy shares of Tenax Therapeutics?
Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tenax Therapeutics' stock price today?
One share of TENX stock can currently be purchased for approximately $1.25.
How big of a company is Tenax Therapeutics?
Tenax Therapeutics has a market capitalization of $1.83 million. Tenax Therapeutics employs 7 workers across the globe.
What is Tenax Therapeutics' official website?
How can I contact Tenax Therapeutics?
Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]
MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe TENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
